Actavis Laboratories recalled 15,944 cartons of Testosterone Gel on November 7, 2025. The recall follows a defect in the side-seal of the containers, which may allow product leakage. Consumers must stop using the product immediately and contact their healthcare providers for guidance.
Defective Container - A defect in the side-seal which allows leakage of product.
Consumers and healthcare providers should stop using this product immediately. Contact Teva Pharmaceuticals USA, Inc or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The affected product is Testosterone Gel 1%, packaged in 30 unit-dose packets containing 2.5 grams each. The recall affects Lot #100068692, which expires on April 30, 2027. The product was distributed nationwide in the U.S.
The recall stems from a defect in the side-seal of the packets that can lead to product leakage. This defect poses a potential risk for users, as the gel is intended for topical use only.
No injuries or adverse effects have been reported related to the defect at this time. The company is urging consumers to take action to prevent any potential risks.
Consumers and healthcare providers should stop using the testosterone gel immediately. Contact Teva Pharmaceuticals USA, Inc. for further guidance regarding the recall.
For more information, consumers can visit the FDA website at www.accessdata.fda.gov or contact Teva Pharmaceuticals USA, Inc.
Get instant alerts for recalls that affect you. Free forever.
Glenmark Pharmaceuticals recalled nearly 97,000 packs of Ondansetron Orally Disintegrating Tablets on December 30, 2025. Defective blister packs may not fully seal, leading to tablets falling out. Consumers should stop using the product immediately and contact healthcare providers.
Novo Nordisk recalled Wegovy (semaglutide) injections on December 19, 2025, after discovering hair in prefilled syringes. The contamination poses a serious hazard to consumers. The recall affects all units distributed nationwide.
Novo Nordisk recalled Wegovy (semaglutide) Injection on December 19, 2025, due to hair found in a prefilled syringe. The recall affects products distributed nationwide in the United States. Consumers should stop using the product immediately and contact their healthcare provider.
Zydus Pharmaceuticals recalled over 2,100 bottles of TraZODONE Hydrochloride Tablets on December 19, 2025. Some tablets have surface dents that may affect medication integrity. Consumers should stop using the product immediately and seek guidance from healthcare providers.
CareFusion 213, LLC recalled 106,400 units of ChloraPrep Triple Swabsticks on December 17, 2025. The recall occurred due to a lack of assurance of sterility. Consumers must stop using the product immediately and contact CareFusion for guidance.
Merck Sharp & Dohme LLC recalled 845 kits of Noxafil Powdermix on December 12, 2025. The recall follows the discovery of potential metal particulates in the product. Consumers should stop using the medication immediately and contact their healthcare provider for further guidance.
Merck Sharp & Dohme LLC recalled 3 single-dose kits of Emend (aprepitant) on December 12, 2025. The recall stems from the potential presence of metal particulates in the medication. Consumers should immediately stop using the product and contact their healthcare provider for guidance.
Beaver-Visitec International recalled five units of the OME6000U Laser and Endoscopy System on December 5, 2025. The recall stems from a manufacturing deviation where ferrites required for the USB cable were not installed. This omission poses a high electrical hazard risk to patients and healthcare providers.